Oculis Holding AG (OCS)
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.59 per share a year ago.
OCS Group to buy Mitie for $4.17 billion
British outsourcer Mitie has agreed to be acquired by rival OCS Group International for a total value of £3.1 billion ($4.17 billion), the companies said on Tuesday.
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals
Oculis NASDAQ: OCS said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug candidate in that indication.
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.77 per share a year ago.
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.76 per share a year ago.
Oculis Holding AG (OCS) Upgraded to Buy: Here's What You Should Know
Oculis Holding AG (OCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.55 per share a year ago.
Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock?
Oculis Holding AG (OCS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.56 per share a year ago.
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.44 per share a year ago.
Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline
Oculis Holding AG (OCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.38 per share a year ago.
